{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T15:35:27Z","timestamp":1765294527197},"reference-count":26,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.leukres.2012.01.027","type":"journal-article","created":{"date-parts":[[2012,4,4]],"date-time":"2012-04-04T04:31:56Z","timestamp":1333513916000},"page":"749-755","source":"Crossref","is-referenced-by-count":7,"title":["Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis"],"prefix":"10.1016","volume":"36","author":[{"given":"Wei","family":"Shi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiarui","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianliang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuankai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2012.01.027_bib0005","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project","volume":"89","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.01.027_bib0010","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1182\/blood.V98.3.787","article-title":"Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray","volume":"98","author":"Hofmann","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.01.027_bib0015","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4049\/jimmunol.171.1.88","article-title":"Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis","volume":"171","author":"Pham","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.leukres.2012.01.027_bib0020","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2005-11-026344","article-title":"Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells","volume":"110","author":"Kawamata","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.01.027_bib0025","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/path.1253","article-title":"Expression of STAT3 and its phosphorylated forms in mantle cell lymphoma cell lines and tumours","volume":"199","author":"Lai","year":"2003","journal-title":"J Pathol"},{"key":"10.1016\/j.leukres.2012.01.027_bib0030","doi-asserted-by":"crossref","first-page":"990","DOI":"10.5858\/2005-129-990-ASOTSP","article-title":"Activation status of the JAK\/STAT3 pathway in mantle cell lymphoma","volume":"129","author":"Yared","year":"2005","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.leukres.2012.01.027_bib0035","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2012.01.027_bib0040","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.leukres.2012.01.027_bib0045","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2012.01.027_bib0050","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1038\/sj.onc.1210365","article-title":"Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo\/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions","volume":"26","author":"Bonavida","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2012.01.027_bib0055","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2012.01.027_bib0060","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.leukres.2012.01.027_bib0065","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1600-0609.2005.00546.x","article-title":"Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma","volume":"76","author":"Heider","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.leukres.2012.01.027_bib0070","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2005.01.9679","article-title":"Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies","volume":"24","author":"O\u2019Connor","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2012.01.027_bib0075","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1349-7006.2009.01360.x","article-title":"Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma","volume":"101","author":"Watanabe","year":"2010","journal-title":"Cancer Sci"},{"key":"10.1016\/j.leukres.2012.01.027_bib0080","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.exphem.2007.06.009","article-title":"Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis","volume":"35","author":"Zhao","year":"2007","journal-title":"Exp Hematol"},{"key":"10.1016\/j.leukres.2012.01.027_bib0085","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/infdis\/137.2.122","article-title":"A method for testing for synergy with any number of agents","volume":"137","author":"Berenbaum","year":"1978","journal-title":"J Infect Dis"},{"key":"10.1016\/j.leukres.2012.01.027_bib0090","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrc780","article-title":"NF-kappaB in cancer: from innocent bystander to major culprit","volume":"2","author":"Karin","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.leukres.2012.01.027_bib0095","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature04870","article-title":"Nuclear factor-kappaB in cancer development and progression","volume":"441","author":"Karin","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2012.01.027_bib0100","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0065-230X(08)60765-4","article-title":"Signal transduction through MAP kinase cascades","volume":"74","author":"Lewis","year":"1998","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.leukres.2012.01.027_bib0105","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1182\/blood-2006-04-015586","article-title":"Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma","volume":"108","author":"Rudelius","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.01.027_bib0110","doi-asserted-by":"crossref","first-page":"7117","DOI":"10.1158\/0008-5472.CAN-03-3500","article-title":"Inhibition of the Raf-MEK1\/2-ERK1\/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab","volume":"64","author":"Jazirehi","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2012.01.027_bib0115","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1158\/0008-5472.CAN-06-2184","article-title":"Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy","volume":"67","author":"Jazirehi","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2012.01.027_bib0120","doi-asserted-by":"crossref","first-page":"7342","DOI":"10.1038\/sj.onc.1204926","article-title":"Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer","volume":"20","author":"Catz","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2012.01.027_bib0125","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/leu.2009.41","article-title":"The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia\/lymphoma cells apoptosis","volume":"23","author":"Zhang","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2012.01.027_bib0130","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1038\/leu.2010.157","article-title":"HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells","volume":"24","author":"Shimizu","year":"2010","journal-title":"Leukemia"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261200046X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261200046X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T04:25:07Z","timestamp":1641961507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521261200046X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S014521261200046X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2012.01.027","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}